Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cidara Therapeutics (CDTX) Operating Expenses: 2016-2024

Historic Operating Expenses for Cidara Therapeutics (CDTX) over the last 9 years, with Dec 2024 value amounting to $177.4 million.

  • Cidara Therapeutics' Operating Expenses rose 409.53% to $88.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $195.5 million, marking a year-over-year increase of 45.16%. This contributed to the annual value of $177.4 million for FY2024, which is 252.34% up from last year.
  • Latest data reveals that Cidara Therapeutics reported Operating Expenses of $177.4 million as of FY2024, which was up 252.34% from $50.3 million recorded in FY2023.
  • Cidara Therapeutics' Operating Expenses' 5-year high stood at $177.4 million during FY2024, with a 5-year trough of $3.7 million in FY2021.
  • For the 3-year period, Cidara Therapeutics' Operating Expenses averaged around $108.6 million, with its median value being $98.0 million (2022).
  • Per our database at Business Quant, Cidara Therapeutics' Operating Expenses crashed by 95.59% in 2021 and then surged by 2,547.32% in 2022.
  • Over the past 5 years, Cidara Therapeutics' Operating Expenses (Yearly) stood at $83.9 million in 2020, then slumped by 95.59% to $3.7 million in 2021, then skyrocketed by 2,547.32% to $98.0 million in 2022, then crashed by 48.60% to $50.3 million in 2023, then spiked by 252.34% to $177.4 million in 2024.